SAMSUNG PHARM. Co., LTD. (KRX:001360)
South Korea
· Delayed Price · Currency is KRW 2,100.00
-15.00 (-0.71%)
Apr 29, 2026, 3:30 PM KST
SAMSUNG PHARM. Co., LTD. Revenue
In the year 2024, SAMSUNG PHARM. Co., LTD. had annual revenue of 44.29B KRW, down -14.75%. SAMSUNG PHARM. Co., LTD. had revenue of 23.34B in the quarter ending September 30, 2019, with 122.70% growth.
Revenue
44.29B
Revenue Growth
-1.90%
P/S Ratio
4.46
Revenue / Employee
184.56M
Employees
240
Market Cap
197.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | -7.66B | -14.75% |
| Dec 31, 2023 | 51.96B | 5.47B | 11.77% |
| Dec 31, 2018 | 46.48B | 4.56B | 10.89% |
| Dec 31, 2017 | 41.92B | -5.27B | -11.18% |
| Dec 31, 2016 | 47.19B | 5.03B | 11.93% |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samil Pharmaceutical Co.,Ltd | 210.25B |
| Jeil Pharmaceutical Co.,Ltd | 567.24B |
| REYON Pharmaceutical | 145.93B |
| JW Lifescience | 257.83B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| Whan In Pharm | 255.21B |
| AptaBio Therapeutics | 3.70B |
| Suheung | 722.31B |